Multifaceted Temozolomide Toxicity in Glioma: Detection & Care.
La Clinica Terapeutica · 01.09.2026 · 177 (5) · 1058-1066
DOI: 10.7417/ct.2026.20105 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift La Clinica Terapeutica, erschienen am 01.09.2026. Verfasst von Ipsita Panda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India. Hauptthemen laut MEDLINE: Temozolomide, Antineoplastic Agents, Alkylating, Glioma, Brain Neoplasms.
Abstract (Originalsprache)
Background
Gliomas are the most common malignant primary brain tumors, and Temozolomide (TMZ) remains a key component of their management. Despite its efficacy, TMZ is associated with adverse drug reactions (ADRs) that may affect quality of life and treatment compliance. This study evaluated the pattern and frequency of ADRs in South Indian glioma patients receiving TMZ, examined demographic associations, and reviewed management strategies.
Methods
A retrospective observational study was conducted at KMC Hospital, Mangalore, India, over the past three years. Thirty-eight patients with histologically confirmed glioma who received oral TMZ were included. Data on demographics, tumor characteristics, treatment schedules, hematological and non-hematological ADRs, management approaches, and outcomes were extracted from medical records and analyzed using SPSS.
Results
The study population was predominantly male (68.4%), with a median age of 45.5 years. Grade 3 and Grade 4 gliomas accounted for 31.6% and 34.2% of cases, respectively. A total of 38 ADRs were documented. The most frequent ADRs were leukocytopenia (9.3%) and itching (9.3%). Management strategies included treatment deferral, dose reduction, antihistamines, nonsteroidal anti-inflammatory drugs, and blood transfusions. Most ADRs resolved without hospitalization. Skin-related reactions typically subsided within 4-14 days, whereas hematological toxicities such as neutropenia required longer recovery periods (22-75 days). The mortality rate was low (5.3%), suggesting effective ADR management.
Conclusion
TMZ-related ADRs in glioma patients are diverse, underscoring the need for vigilant monitoring of both hematological and non-hematological toxicities. Individualized management and careful tracking of recovery times can improve treatment tolerance and patient quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India.
- Department of Radiation Oncology, Kasturba Medical College Mangalore, Manipal Academy of Higher Education, Manipal, India.
Zitieren
APA
Panda, I., Athiyamaan, M. S., Bharathi R, P., & Shamsudeen, M. (2026). Multifaceted Temozolomide Toxicity in Glioma: Detection & Care. La Clinica Terapeutica, 177(5), 1058-1066. https://doi.org/10.7417/ct.2026.20105
Vancouver
Panda I, Athiyamaan MS, Bharathi R P, Shamsudeen M. Multifaceted Temozolomide Toxicity in Glioma: Detection & Care. La Clinica Terapeutica. 2026;177(5):1058-1066. doi:10.7417/ct.2026.20105
BibTeX
@article{Panda2026,
author = {Panda, Ipsita and Athiyamaan, M S and Bharathi R, Poovizhi and Shamsudeen, Manaal},
title = {Multifaceted Temozolomide Toxicity in Glioma: Detection & Care},
journal = {La Clinica Terapeutica},
year = {2026},
volume = {177},
number = {5},
pages = {1058--1066},
doi = {10.7417/ct.2026.20105}
}
EUVIMED